Even more significant than iGuard's 2 million user base is its contributions to improved health care since being launched by Quintiles in 2007:
Distribution of drug safety alerts and recalls to over 500,000 Americans; Production of over 14 million personalized drug interaction reports; Delivery of timely information to 1.3 million Americans affected by at least one significant potential drug-drug or drug-disease interaction; Real time effectiveness and side-effect tracking for over 300 prescription and over-the-counter medicines; Involvement of over 73,000 iGuard users in 92 clinical studies, helping to lower the cost and increase the speed of bringing better medications to market. iguard/Recent Posts
- Neither vitamin E nor metformin reduces liver enzymes in children with fatty liver disease: Study
- ETP makes investment to support development of ICVrx's targeted epilepsy drug technology
- Drug subsidy issues out of PBS ™ hands - almost
- Roche introduces new Accu-Chek Mobile glucose monitoring device
- New screening marker can detect pancreatic cancer
- AAN honors BIDMC neurologist with Epilepsy Award
- Kadmon Pharmaceuticals and Nano Terra announce worldwide licensing agreement
- Individuals on SSRIs still exhibit depressive symptoms
- Symposium to explore energy balance in physiologically maladaptive Homo sapiens
- Research roundup: New hips, Medicare & hospital stays; Medicaid update
- Health Partners earns NCQA accreditation for high quality care